On June 2, 2025, Blueprint Medicines (BPMC, Financial) received a stock rating downgrade from the analyst Louise Chen of Scotiabank. The rating was adjusted from 'Sector Outperform' to 'Sector Perform'. This change indicates a more cautious outlook on the stock's performance in comparison to the broader market sector.
In addition to the rating adjustment, Scotiabank announced a price target of USD 135.00 for Blueprint Medicines (BPMC, Financial). This target provides investors with insights into the potential market value of the stock based on the current analysis from Scotiabank.
Given these updates, stakeholders and potential investors in Blueprint Medicines (BPMC, Financial) may need to reassess their investment strategies considering the revised outlook and price target set by Scotiabank's analyst.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 16 analysts, the average target price for Blueprint Medicines Corp (BPMC, Financial) is $122.00 with a high estimate of $150.00 and a low estimate of $83.00. The average target implies an downside of 4.43% from the current price of $127.66. More detailed estimate data can be found on the Blueprint Medicines Corp (BPMC) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Blueprint Medicines Corp's (BPMC, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Blueprint Medicines Corp (BPMC, Financial) in one year is $191.68, suggesting a upside of 50.15% from the current price of $127.655. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Blueprint Medicines Corp (BPMC) Summary page.
